Patents by Inventor Stephen Comiskey

Stephen Comiskey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10232011
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: March 19, 2019
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Publication number: 20190002501
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: June 5, 2018
    Publication date: January 3, 2019
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Patent number: 10034836
    Abstract: The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: July 31, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Stephen Comiskey
  • Publication number: 20180207229
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: March 19, 2018
    Publication date: July 26, 2018
    Inventors: Stephen COMISKEY, Rong FENG, John FOSS, Kunwar SHAILUBHAI
  • Patent number: 10011637
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 3, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Patent number: 9925231
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: March 27, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Patent number: 9919024
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: March 20, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Publication number: 20170202904
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: March 23, 2017
    Publication date: July 20, 2017
    Inventors: Stephen COMISKEY, Rong FENG, John FOSS, Kunwar SHAILUBHAI
  • Publication number: 20170202903
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: March 23, 2017
    Publication date: July 20, 2017
    Inventors: Stephen COMISKEY, Rong FENG, John FOSS, Kunwar SHAILUBHAI
  • Publication number: 20170129925
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Application
    Filed: January 13, 2017
    Publication date: May 11, 2017
    Applicant: Synergy Pharmaceuticals Inc.
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jian, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • Patent number: 9616097
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: April 11, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Patent number: 9610321
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 4, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Patent number: 9580471
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: February 28, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • Publication number: 20160145307
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: June 5, 2014
    Publication date: May 26, 2016
    Inventors: Kunwar SHAILUBHAI, Stephen COMISKEY, Rong FENG, Juncai BAI, Ruoping ZHANG, Jun JIA, Junfeng ZHOU, Qiao ZHAO, Guoqing ZHANG
  • Publication number: 20150366935
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: September 4, 2015
    Publication date: December 24, 2015
    Inventors: Stephen COMISKEY, Rong FENG, John FOSS, Kunwar SHAILUBHAI
  • Publication number: 20150359749
    Abstract: The invention provides novel formulations of guanylate cyclase-C(“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: June 11, 2014
    Publication date: December 17, 2015
    Inventors: Kunwar SHAILUBHAI, Stephen COMISKEY
  • Publication number: 20140155575
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Application
    Filed: March 1, 2012
    Publication date: June 5, 2014
    Applicant: SYNERGY PHARMACEUTICALS INC.
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jian, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • Publication number: 20120237593
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: March 15, 2012
    Publication date: September 20, 2012
    Applicant: Synergy Pharmaceuticals Inc.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Publication number: 20100221329
    Abstract: The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: December 3, 2009
    Publication date: September 2, 2010
    Applicant: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Stephen Comiskey
  • Publication number: 20070277925
    Abstract: A method and product for reducing reflected light glare into a human's eyes from the human's cheeks while simultaneously providing a non-verbal communication to others is provided, especially for use by participants in athletic contests. Underneath the human's eyes on the cheeks at a reflective location on the cheeks at which incident direct or indirect light is likely to be reflected into a human's eyes a non-toxic, non-reflective colored and finished material in the form of a predefined clearly demarcated geometric shape is applied. Within a week after the application (typically within less than a few hours after the athletic contest is over) the non-reflective material is removed. The non-reflective material may comprise eye black, applied using a stencil, or it may comprise a temporary tattoo or decal, applied in the conventional manner. The shape preferably is a sports apparel or equipment manufacturer's or distributor's logo and/or letters, or a team name, mascot or logo.
    Type: Application
    Filed: July 18, 2007
    Publication date: December 6, 2007
    Inventors: Stephen Comiskey, Barrett Comiskey